Eli Lilly And Co (NYSE:LLY) saw a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 16,682,000 shares, an increase of 45.6% from the July 31st total of 11,459,200 shares. Approximately 2.0% of the shares of the company are short sold. Based on an average daily trading volume, of 3,990,000 shares, the short-interest ratio is currently 4.2 days.

LLY has been the subject of several analyst reports. Bank of America set a $120.00 price objective on shares of Eli Lilly And Co and gave the stock a “neutral” rating in a report on Tuesday. ValuEngine downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Friday, June 28th. Goldman Sachs Group initiated coverage on shares of Eli Lilly And Co in a report on Tuesday, May 28th. They issued a “buy” rating and a $135.00 price objective for the company. Finally, Zacks Investment Research downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Tuesday, May 21st. Nine investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Eli Lilly And Co has an average rating of “Buy” and an average price target of $122.93.

NYSE:LLY traded down $0.58 during trading hours on Friday, hitting $110.89. The stock had a trading volume of 2,828,022 shares, compared to its average volume of 8,695,222. The company has a 50 day simple moving average of $111.51 and a two-hundred day simple moving average of $116.94. The company has a debt-to-equity ratio of 4.98, a current ratio of 1.13 and a quick ratio of 0.87. Eli Lilly And Co has a one year low of $104.17 and a one year high of $132.13. The firm has a market capitalization of $107.26 billion, a price-to-earnings ratio of 19.98, a P/E/G ratio of 1.96 and a beta of 0.16.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $1.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.45 by $0.05. Eli Lilly And Co had a net margin of 33.76% and a return on equity of 70.86%. The firm had revenue of $5.64 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period last year, the firm earned $1.48 EPS. The business’s quarterly revenue was up .9% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly And Co will post 5.73 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th were issued a $0.645 dividend. This represents a $2.58 annualized dividend and a yield of 2.33%. The ex-dividend date was Wednesday, August 14th. Eli Lilly And Co’s payout ratio is 46.49%.

In related news, SVP Stephen F. Fry sold 9,452 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $115.00, for a total value of $1,086,980.00. Following the completion of the transaction, the senior vice president now directly owns 100,211 shares of the company’s stock, valued at approximately $11,524,265. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Alfonso G. Zulueta sold 19,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $112.91, for a total transaction of $2,201,745.00. Following the completion of the transaction, the senior vice president now directly owns 38,306 shares of the company’s stock, valued at $4,325,130.46. The disclosure for this sale can be found here. 0.11% of the stock is currently owned by company insiders.

A number of large investors have recently made changes to their positions in the business. Hancock Whitney Corp lifted its holdings in shares of Eli Lilly And Co by 0.7% during the 2nd quarter. Hancock Whitney Corp now owns 32,048 shares of the company’s stock worth $3,551,000 after acquiring an additional 233 shares during the last quarter. EP Wealth Advisors LLC lifted its holdings in shares of Eli Lilly And Co by 28.8% during the 2nd quarter. EP Wealth Advisors LLC now owns 6,463 shares of the company’s stock worth $716,000 after acquiring an additional 1,447 shares during the last quarter. Atria Investments LLC lifted its holdings in shares of Eli Lilly And Co by 1.6% during the 2nd quarter. Atria Investments LLC now owns 8,322 shares of the company’s stock worth $944,000 after acquiring an additional 133 shares during the last quarter. RFG Advisory LLC lifted its holdings in shares of Eli Lilly And Co by 16.0% during the 2nd quarter. RFG Advisory LLC now owns 3,085 shares of the company’s stock worth $340,000 after acquiring an additional 425 shares during the last quarter. Finally, BlackRock Inc. lifted its holdings in shares of Eli Lilly And Co by 1.5% during the 2nd quarter. BlackRock Inc. now owns 61,979,145 shares of the company’s stock worth $6,866,670,000 after acquiring an additional 898,845 shares during the last quarter. 76.78% of the stock is owned by hedge funds and other institutional investors.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: How to trade on quiet period expirations

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.